DeepMed Research

Alpha-1-proteinase inhibitor

Generic Name: Alpha-1-proteinase inhibitor

Brand Names: Aralast, Glassia, Prolastin, Prolastin-C, Respreeza, Zemaira

Drug Type: Biotech

CAS Number: 9041-92-3

Unique Ingredient Identifier: F43I396OIS

Background: Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.

Indication: For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.

Associated Conditions: Emphysema

Associated Therapies: Augmentation, Maintenance therapy

Clinical Trials

Effect of Alpha-1 Antitrypsin Supplementation on Alcohol-Associated Hepatitis

Phase 2

Not yet recruiting

Conditions: Alcohol-Associated Hepatitis

Interventions: Drug: Alfa1 Antitrypsin

First Posted Date: 2024-09-03

Last Posted Date: 2025-03-06

Lead Sponsor: Medical University Innsbruck

Target Recruit Count: 16

Registration Number: NCT06582329

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Austria

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Phase 2

Active, not recruiting

Conditions: Alpha 1-Antitrypsin Deficiency
Emphysema

Interventions: Drug: SAR447537
Drug: Zemaira

First Posted Date: 2023-05-12

Last Posted Date: 2025-01-16

Lead Sponsor: Sanofi

Target Recruit Count: 99

Registration Number: NCT05856331

Locations: 🇺🇸
University of Alabama at Birmingham- Site Number : 105, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
St Joseph's Hospital and Medical Center- Site Number : 126, Phoenix, Arizona, United States

and more 78 locations

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Phase 3

Withdrawn

Conditions: Covid19
Pneumonia, Viral

Interventions: Drug: Antiviral Agents
Drug: alpha1-proteinase inhibitor

First Posted Date: 2020-12-19

Last Posted Date: 2020-12-21

Lead Sponsor: Blessing Corporate Services, Inc

Registration Number: NCT04675086

Locations: 🇺🇸
Blessing Corporate Services, Inc, Hannibal, Missouri, United States

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Phase 3

Recruiting

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: Placebo
Drug: Alpha 1-Antitrypsin

First Posted Date: 2019-12-18

Last Posted Date: 2025-01-17

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 220

Registration Number: NCT04204252

Locations: 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
🇬🇧
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
🇧🇪
University Hospital (UZ) Leuven, Leuven, Belgium

and more 6 locations

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

Phase 2

Completed

Conditions: Graft-versus-host-disease
GVHD

Interventions: Drug: Alpha 1-Antitrypsin

First Posted Date: 2018-03-08

Last Posted Date: 2021-07-12

Lead Sponsor: John Levine

Target Recruit Count: 30

Registration Number: NCT03459040

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 2 locations

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Phase 2

Withdrawn

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: Glassia
Drug: OctaAlpha1

First Posted Date: 2017-12-28

Last Posted Date: 2018-04-10

Lead Sponsor: Octapharma

Registration Number: NCT03385395

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Conditions: Graft Vs Host Disease
Alpha 1-Antitrypsin Deficiency
Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant
Steroid Refractory Acute Graft Versus Host Disease
Alpha-1 Proteinase Inhibitor
Alpha-1 Protease Inhibitor Deficiency
Acute-graft-versus-host Disease
Graft-versus-host-disease

First Posted Date: 2017-06-01

Last Posted Date: 2020-10-05

Lead Sponsor: Impatients N.V. trading as myTomorrows

Registration Number: NCT03172455

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

Phase 1

Completed

Conditions: Chronic Pancreatitis

Interventions: Drug: Placebo
Drug: Prolastin-C

First Posted Date: 2016-10-27

Last Posted Date: 2023-06-29

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 48

Registration Number: NCT02947087

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Phase 4

Active, not recruiting

Conditions: Pancreatitis, Chronic; Diabetes; Transplant

Interventions: Drug: etanercept
Drug: Alpha 1-Antitrypsin

First Posted Date: 2016-03-21

Last Posted Date: 2023-08-14

Lead Sponsor: University of Minnesota

Target Recruit Count: 44

Registration Number: NCT02713997

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Phase 2

Completed

Conditions: Transplantation, Lung Rejection

Interventions: Drug: GLASSIA® and Institution standard of care (SOC)

First Posted Date: 2015-11-25

Last Posted Date: 2021-09-01

Lead Sponsor: Kamada, Ltd.

Target Recruit Count: 30

Registration Number: NCT02614872

Locations: 🇮🇱
Pulmonary Institute - Rabin Medical Center, Petach Tikva, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy